SCHEMBL7648002

SCHEMBL7648002

Fc1ccc(OCCCN2Cc3ccccc3C2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.81
HTR1A P08908 4/20 0.79
DRD2 P14416 4/20 0.79
HTR2A P28223 4/20 0.79
DRD3 P35462 4/20 0.79
HRH1 P35367 3/20 0.79
HTR7 P34969 2/20 0.79
HTR2B P41595 1/20 0.79
TMEM97 Q5BJF2 1/20 0.61
SIGMAR1 Q99720 1/20 0.61
USP2 O75604 1/20 0.59
ALDH1A1 P00352 1/20 0.59
HPGD P15428 1/20 0.59
TDP1 Q9NUW8 1/20 0.58
MEN1 O00255 2/20 0.56
KMT2A Q03164 2/20 0.56
LMNA P02545 1/20 0.56
HTT P42858 1/20 0.56
DRD1 P21728 2/20 0.56
ADRA2C P18825 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20364968 0.90 HTR5A (1.00) HTR5AHTR1ADRD2HTR2ADRD3
Hydrochloric Acid SCHEMBL20359282 0.89 HTR1A (1.00) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL1728918 0.81 USP2 (0.78) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL12359053 0.79 USP2 (0.91) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL13698800 0.78 USP2 (0.73) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL7434707 0.77 HRH3 (0.88) HRH1USP2ALDH1A1HPGDMEN1
Hydrochloric Acid SCHEMBL1730768 0.77 USP2 (0.71) HTR1ADRD2HTR2ADRD3HRH1
SCHEMBL7246965 0.76 HTR5A (0.79) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL7647211 0.76 DRD2 (0.82) HTR5AHTR1ADRD2HTR2ADRD3
SCHEMBL7389246 0.75 MEN1 (0.67) HTR5AHTR1ADRD2HTR2ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US disclosed
WO-2000000472-A1 5-HT7 RECEPTOR ANTAGONISTS DU PONT PHARMACEUTICALS COMPANY (US) 2000-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A HTR5A 2/4885HTR1A 3/4885DRD2 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.